Teknova (Hollister, Calif.) announced today that it has completed the FDA notification process for its CDC formulation viral transport medium (VTM).
Notification process compilation means the VTM is in compliance with FDA’s COVID-19 Transport Media Policy, July 2020 guidelines. Teknova is now offering the VTM for commercial distribution after scaling up manufacturing within six months.
Teknova presently has the ability to make 50,000 tubes of VTM daily, and plans to more than triple its production capacity in the company months.
“We are excited to have been able to go from zero production to FDA notification within six months and further contribute to combating COVID-19”, Teknova CEO Stephen Gunstream said in a news release.
Filed Under: Drug Discovery and Development, Infectious Disease